EUVIMEDEUVIMED entdecken
Crossref

Expert consensus for prevention, diagnosis and management of persistent chemotherapy‐induced alopecia

Azael Freites-Martinez iD, Zoe Apalla iD, Jerry Shapiro, Matilde Iorizzo, Lidia Rudnicka iD, Kristen Lo Sicco iD, Vasiliki Nikolaou iD, Rodrigo Pirmez iD, Anita Takwale, Davide Fattore iD, Brittany Dulmage, Bianca Maria Piraccini iD und 4 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.70021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Azael Freites-Martinez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain. Hauptthemen laut MEDLINE: Alopecia, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Persistent chemotherapy‐induced alopecia (pCIA) is a distressing side effect of antineoplastic agents, imposing significant psychological burdens on cancer survivors. Despite its impact, there are no standardized guidelines for diagnosis, prevention or management.

Objectives

To establish consensus‐based definitions, diagnostic criteria, grading systems and management recommendations for pCIA.

Methods

A two‐round Delphi method was conducted with 15 international experts in supportive oncodermatology and hair diseases from both Europe and the Americas. Statements were rated on a 5‐point Likert scale, with a strong consensus defined as ≥75% agreement. Statements that did not achieve strong consensus in the first round were revised based on expert feedback and re‐evaluated in a second‐round survey.

Results

Strong consensus was reached on 47 statements (75.8%). pCIA was defined as non‐scarring alopecia persisting beyond 6 months post‐chemotherapy. Causes were attributed to the destruction of hair follicle stem cells, with taxanes, thiotepa and anthracyclines identified as key contributors. Consensus emphasized the importance of prevention of pCIA through scalp cooling devices, and the early intervention with topical or low‐dose oral minoxidil was also recommended. Interestingly, the experts did not recommend the use of bicalutamide, oral finasteride and dutasteride (including in mesotherapy) for breast cancer patients with pCIA, citing potential safety concerns.

Conclusions

This Delphi study established unified guidelines for pCIA, providing clinicians with a clear framework for diagnosis and treatment. Highlighting prevention through scalp cooling and timely interventions may improve outcomes for cancer survivors. Further research is necessary to assess new treatments and the long‐term impact of chemotherapy on hair follicles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlopeciaAntineoplastic AgentsHumansConsensusDelphi TechniqueMinoxidil

Stichwörter der Autor:innen

Delphi consensusalopeciaalopecia chemotherapy‐inducedantineoplastic agentsbreast neoplasmsdrug‐induced alopeciadutasterideendocrine therapyexpert panel recommendationsfinasteridehair diseasesminoxidilneoplasmspCIA managementscalp cooling

Substanzen

Antineoplastic AgentsMinoxidil

Autor:innen und Institutionen

  • Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain.
  • First Department of Dermatology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York City, New York, USA.
  • Private Dermatology Practice, Lugano, Switzerland.
  • Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
  • 1st Department of Dermatology, Andreas Syggros Hospital, National & Kapodistrian University of Athens, Medical School, Athens, Greece.

ORCID-Profile: Azael Freites-Martinez, Zoe Apalla, Lidia Rudnicka, Kristen Lo Sicco, Vasiliki Nikolaou, Rodrigo Pirmez, Davide Fattore, Bianca Maria Piraccini, Vincent Sibaud, Michela Valeria Rita Starace

Zitieren

APA

Freites-Martinez, A., Apalla, Z., Shapiro, J., Iorizzo, M., Rudnicka, L., Lo Sicco, K., Nikolaou, V., Pirmez, R., Takwale, A., Fattore, D., Dulmage, B., Piraccini, B. M., Vano-Galvan, S., Lacouture, M., Sibaud, V., & Starace, M. V. R. (2025). Expert consensus for prevention, diagnosis and management of persistent chemotherapy‐induced alopecia. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70021

Vancouver

Freites-Martinez A, Apalla Z, Shapiro J, Iorizzo M, Rudnicka L, Lo Sicco K, et al. Expert consensus for prevention, diagnosis and management of persistent chemotherapy‐induced alopecia. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.70021

BibTeX
@article{FreitesMartinez2025,
  author = {Freites-Martinez, Azael and Apalla, Zoe and Shapiro, Jerry and Iorizzo, Matilde and Rudnicka, Lidia and Lo Sicco, Kristen and Nikolaou, Vasiliki and Pirmez, Rodrigo and Takwale, Anita and Fattore, Davide and Dulmage, Brittany and Piraccini, Bianca Maria and Vano-Galvan, Sergio and Lacouture, Mario and Sibaud, Vincent and Starace, Michela Valeria Rita},
  title = {Expert consensus for prevention, diagnosis and management of persistent chemotherapy‐induced alopecia},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.70021}
}
Kostenlos starten →